Case Study | September 08, 2014

Toshiba’s Infinix-i Cardiovascular X-ray Ushers in a New Era of Cost-Effective Disease Treatment

PinnacleHealth developed a successful TAVR program based on the heart team approach and the advanced hybrid OR imaging technology

Infinix-i, TAVR, TOSHIBA

The flexible design of the Infinix-i streamlines procedures and allows operators to obtain a wide range of imaging angles without repositioning the patient.

Brijeshwar Maini, M.D., director of advanced cardiac and endovascular interventional laboratory, director of cardiovascular research and education and medical director of the PinnacleHealth CVI Valve Clinic

After several years of trials and increasing clinical use, transcatheter aortic valve replacement (TAVR) has reached a tipping point. It is quickly becoming the standard of care for ill patients suffering from aortic valve stenosis who are not eligible for open heart surgery. Implemented successfully, TAVR procedures improve outcomes and quality of life for patients while reducing costs for hospitals. 

 

To get different clinical disciplines working together, PinnacleHealth created a “heart team” that connects the knowledge base of cardiologists and interventionalists with the expertise of surgeons. As the team worked together and continued to become more familiar with each other and the procedure, the results naturally improved. A by-product of the team’s success was that procedure volumes also increased as the team received more referrals.

For hospitals that are able to push the envelope and innovate with cutting-edge treatments like TAVR, the economic benefits today can be attainable and quantified. 
 
“When TAVR was in its infancy, we developed the relationship between the surgical and percutaneous expertise of our clinicians,” said Brijeshwar Maini, M.D., director of advanced cardiac and endovascular interventional laboratory, director of cardiovascular research and education and medical director of the PinnacleHealth CVI Valve Clinic. “This collaboration enabled us to explore innovative ways to improve patient outcomes with more efficiency.” 
 
The Right Technology 
For its imaging system, PinnacleHealth selected Toshiba’s Infinix-i cardiovascular system for its hybrid OR lab, providing the versatility needed for innovative procedures and dose management optimizing tools for longer procedures. The system offers a mechanical design to provide excellent access and coverage. Its flexible C-arm movement and high-resolution images at various angles enable physicians to conduct advanced TAVR procedures with maximum efficacy. 
 
“The system’s flexible design streamlines procedures, allowing us to obtain a wide range of imaging angles without repositioning the patient,” Maini said. “The Infinix-i, combined with the OR table, produces a hybrid lab that is ready for today’s exams and tomorrow’s innovations.” 
 
State-of-the-art 3mensio and CAAS software are also integrated into the system, making TAVR planning and real-time deployment even more accurate and efficient. 
 
As one of the finest TAVR programs available today, PinnacleHealth has leveraged its heart team approach and the latest technology to achieve fewer readmissions and lower costs.
 
The Business Case for TAVR 
There is often a misconception that newer procedures are more expensive and result in a greater burden for the healthcare system. For TAVR programs, the opposite is true, as these procedures can help reduce readmissions of heart failure patients who are the sickest and most vulnerable to long medical stays. 
 
“For hospitals that are able to push the envelope and innovate with cutting-edge treatments like TAVR, the economic benefits are tangible and quantifiable,” Maini said. 
 
The growth in TAVR procedures and the ability to conduct them with the latest in imaging technology is bringing less invasive, more efficient and lower cost treatments to both patients and healthcare providers.
 

Keys to Developing a Successful TAVR Program:

• Developing the Right Lab: The most important decision for a TAVR program is designing the right lab. Toshiba’s Infinix-i cardiovascular system provides unmatched flexibility in system design and configurations to meet clinicians’ needs to conduct these procedures with ease. 

• Improving Patient Care: Combining long-term strategy and
collaborative planning with innovative, flexible technology can have
a very positive impact on patient care and results. 

• Economic Upside: TAVR programs can help reduce readmissions of heart failure patients. Implemented and managed well, a TAVR program should save hospitals money.

For more information: www.medical.toshiba.com

Related Content

The Foldax Tria surgical valve reimagines the heart valve by incorporating a new, proprietary biopolymer, what the vendor calls LifePolymer, with an innovative valve design intended to eliminate calcification, withstand stresses and strains without failure, and restore patient quality of life without lifelong use of anticoagulants. Tria is also the first heart valve to be robotically manufactured, reducing variability, enabling high precision, repeatability and better quality control.
News | Heart Valve Technology | June 23, 2020
June 23, 2020 – Heart valve start-up Foldax is looking to reinventi
SMT Enters Structural Heart Market With Acquisition of Vascular Concepts. The company's Hydra TAVR (TAVI) valve gained European CE mark clearance in June 2020.
News | Heart Valve Technology | June 19, 2020
June 19, 2020 — SMT (Sahajanand Medical Technologies Pvt.
SMT (Sahajanand Medical Technology Private Ltd.), a leading medical device company of India focused on cardiology, announced it Hydra transcatheter aortic valve replacement (TAVR) device received European CE mark approval. It is indicated for the treatment of patients diagnosed with aortic stenosis. #SMT #HYDRA #TAVR

The self-expanding SMT Hydra transcatheter aortic valve replacement (TAVR) device.

Feature | Heart Valve Technology | June 09, 2020
June 9, 2020 — SMT (Sahajanand Medical Technology Private Ltd.), a leading medical device company in India focused on
News | Heart Valve Technology | June 08, 2020
June 8, 2020 — Edwards Lifesciences Corp.
Edwards Lifesciences Pascal Tricuspid Valve Transcatheter Repair System Approved in Europe
News | Heart Valve Technology | May 18, 2020
May 18, 2020 — The Edwards Lifesciences Corp.
Key TAVR Takeaways From ACC 2020
Feature | Heart Valve Technology | April 20, 2020 | Dave Fornell, Editor
Some U.S.
Abbott announced its TriClip Transcatheter Tricuspid Valve Repair (TTVR) System has received European CE mark clearance as a non-surgical treatment for people with a tricuspid valve regurgitation (TR). 
Feature | Heart Valve Technology | April 09, 2020
April 9, 2020 — Abbott announced its TriClip Transcatheter Tricuspid Valve Repair (TTVR) System has received European
The Edwards Lifesciences Cardioband for tricuspid valve regurgitation. #COVID19 #coronavirus

The Edwards Lifesciences Cardioband for tricuspid valve regurgitation is one of the device trials being paused for the duration of the COVID-19 outbreak.

News | Heart Valve Technology | March 30, 2020
March 30, 2020 — Edwards Lifesciences Corp.
Conclusions from the TAVR vs surgery trial for aortic valve replacement in the U.K. presented by William D. Toff, M.D. at ACC 20. #ACC20 #ACC2020 #TAVR #TAVR

Conclusions from the real world TAVR vs. surgery trial for aortic valve replacement outcomes in the U.K., presented by William D. Toff, M.D. at ACC 20. 

News | Heart Valve Technology | March 30, 2020
March 30, 2020 — Patients in the United Kingdom (U.K.) who underwent transcatheter aortic valve replacement (TAVR) di